Business
Penumbra develops thrombectomy and vascular medical devices.
Penumbra grew revenue, remained profitable, generated positive free cash flow at a 13.5% operating margin. Capital spending and stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 17.5%OK
- Profitability — Net income grew 1168.1% to $177.687M from $14.012MOK
- Cash flow — Free cash flow grew 18.8% to $174.934M from $147.299MOK
- Margins — Operating margin expanded 1270 bps to 13.48%OK
- Accounting — Capital spending and stock compensation grew faster than revenueNote
- Insiders — 0 purchases and 25 salesWatch
Where the revenue comes from
Fiscal 2025, as Penumbra Inc reports it. History and quarterly detail are in the app.
- Thrombectomy$947.9M
- Embolization and Other$455.7M
Leadership changes
From Penumbra Inc's own filings, the day they're filed.
- Shruthi Narayan · President · appointmenteff. 2025-09-01
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Penumbra Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.